세계의 레지오넬라균 검사 시장 : 시장 규모, 점유율 및 동향 분석(유형별, 최종 용도별, 지역별), 부문별 예측(2025-2030년)

Legionella Testing Market Size, Share, & Trends Analysis Report By Type (Water Testing, IVD Testing), By End Use (Microbial Culture, Direct Fluorescent Antibody (DFA) Stain, PCR, Others), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,269,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,659,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,438,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 레지오넬라균 검사 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 레지오넬라균 검사 시장 규모는 2030년까지 5억 4,740만 달러에 달할 것으로 예측되며, 2025년부터 2030년까지 CAGR 8.2%로 성장할 것으로 예측되고 있습니다.

폰티악 열과 폐렴과 같은 레지오넬라 질환의 발생률이 증가하는 것은 시장 성장의 주요 요인 중 하나입니다.

시기적절한 레지오넬라균 검사에 대한 지향 증가는 신속한 회복과 환자의 예후 개선과 같은 이점에 기인합니다.

레지오넬라균 검사 프로그램, 계발 캠페인, 수질 안전 규제 등 정부 주도의 대처에 의해 레지오넬라 사례의 검출과 관리가 세계적으로 증가할 것으로 추정됩니다.

레지오넬라균 검사 시장 : 분석 개요

• 유럽은 레지오넬라증에 관한 의식이 높아지고, 세련된 의료 시스템, 공중위생 보호 이니셔티브, 영국이나 독일 등의 국가에서의 검사 의무화 규제 등의 요인에 의해 2024년에는 39.0% 이상의 점유율로 세계의 레지오넬라균 검사 시장을 독점했습니다.
• IVD 검사 분야는 예측 기간 동안 현저한 CAGR을 나타낼 전망입니다.
• 최종 용도별로는 PCR 분야가 2024년 매출액 점유율 37.7%로 시장을 독점했습니다.
• 인구동태, 환경 요인등의 요인에 의해 많은 지역에서 기록되는 레지오넬라균 발생이 증가해, 수요를 견인할 것으로 예측됩니다.
• 의료 시스템의 대폭적인 강화, 적시 개입에 관한 의식 상승, 공중 위생에 관련하는 정부의 이니셔티브는 예측 기간 중에 이 업계에 유리한 성장 기회를 추가할 것으로 예측됩니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 레지오넬라균 검사 시장 : 변동 요인, 경향, 범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 레지오넬라균 검사 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 레지오넬라균 검사: 유형별 추정 및 동향 분석

• 유형별 대시보드
• 레지오넬라균 검사 시장 : 변동 분석, 유형별
• 레지오넬라균 검사 : 시장 규모와 동향 분석, 유형별(2018-2030년)
• 수질검사
  • 시장 추계 및 예측(2018-2030년)
• 체외(IVD) 진단 검사
  • 시장 추계 및 예측(2018-2030년)

제5장 레지오넬라균 검사 시장 : 최종 용도별 추정 및 동향 분석

• 용도별 대시보드
• 레지오넬라균 검사 시장 : 변동 분석, 최종 용도별
• 레지오넬라균 검사 : 시장 규모와 동향 분석, 최종 용도별(2018-2030년)
• 미생물 배양
• 직접 형광 항체(DFA) 염색
• PCR
• 기타

제6장 레지오넬라균 검사 시장 : 지역별 추정 및 동향 분석

• 지역별 대시보드
• 시장 점유율 분석 : 지역별(2024년 및 2030년)
• 레지오넬라균 검사 시장 :주요 포인트, 지역별
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 기업의 히트맵 분석(2024년)
• 기업 프로파일
  • Abbott
  • Beckman Coulter, Inc
  • BD
  • Bio-Rad Laboratories, Inc.
  • BIOMERIEUX
  • Eiken Chemical Co., Ltd.
  • Hologic, Inc.
  • Pro Lab Diagnostics Inc.
  • QIAGEN
  • F. Hoffmann-La Roche Ltd.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.

JHS

영문 목차

영문목차

Legionella Testing Market Growth & Trends:

The global legionella testing market size is anticipated to reach USD 547.4 million by 2030 and is expected to experience a CAGR of 8.2% from 2025 to 2030, according to a new report by Grand View Research, Inc., the increasing incidence of legionella diseases, such as Pontiac fever and pneumonia, is one of the major factors contributing to the market's growth. According to the World Health Organization (WHO), nearly 10 to 15 new cases per million population are identified every year in Europe, Australia, and the U.S.

The growing inclination towards timely legionella testing can be attributed to advantages such as speedy recovery and improved patient outcome. Additionally, integrating legionella testing methods with advanced diagnostic technologies such as PCR and point-of-care testing are expected to fuel growth of this market in the forecast period.

Government-sponsored initiatives, including legionella testing programs, awareness campaigns, and water safety regulations, are estimated to increase the detection and management of legionella cases globally. For instance, in Europe, stringent regulations mandate regular Legionella testing in water systems, which is expected to boost the demand for advanced Legionella testing methods.

Legionella Testing Market Report Highlights:

• Europe dominated the global legionella testing market with over 39.0% share in 2024 owing to factors such as increasing awareness regarding legionellosis, sophisticated healthcare systems, public health protection initiatives, and mandatory testing regulations in countries such as the UK and Germany.
• The IVD testing segment is expected to grow at a significant CAGR over the forecast period.
• Based on end use, the PCR segment dominated market with revenue share of 37.7% in 2024. PCR enables the precise and rapid detection of bacteria through its high sensitivity and quick turnaround time.
• Increasing legionella outbreaks recorded in numerous regions driven by factors such as demography, environmental factors and others are expected to drive demand.
• Significantly enhanced healthcare systems, growing awareness regarding timely interventions, and government initiatives associated with public health are likely to add lucrative growth opportunities to this industry over forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. End Use
  • 1.2.3. Regional Scope
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. End Use outlook
  • 2.2.3. Regional out
• 2.3. Competitive Insights

Chapter 3. Legionella Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Legionella Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Legionella Testing: Type Estimates & Trend Analysis

• 4.1. Type Segment Dashboard
• 4.2. Legionella Testing Market: Type Movement Analysis
• 4.3. Global Legionella Testing Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Water Testing
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. IVD Testing
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Legionella Testing Market: End Use Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Legionella Testing Market: Application Movement Analysis
• 5.3. Global Legionella Testing Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Microbial culture
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Direct Fluorescent Antibody (DFA) Stain
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. PCR
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Legionella Testing Market: Regional Estimates & Trend Analysis

• 6.1. Regional Segment Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Legionella Testing market by Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. U.K.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.K. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.2.5. Key country dynamics
    • 6.5.2.6. Regulatory framework/ reimbursement structure
    • 6.5.2.7. Competitive scenario
    • 6.5.2.8. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Norway
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Sweden
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key country dynamics
    • 6.5.8.2. Regulatory framework/ reimbursement structure
    • 6.5.8.3. Competitive scenario
    • 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Australia
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Brazil
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Aregentina
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. MEA
  • 1.1.2. South Africa
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Saudi Arabia
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. UAE
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.4. Kuwait
    • 6.8.4.1. Key country dynamics
    • 6.8.4.2. Regulatory framework/ reimbursement structure
    • 6.8.4.3. Competitive scenario
    • 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company heat map analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Abbott
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Beckman Coulter, Inc
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. BD
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Bio-Rad Laboratories, Inc.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. BIOMERIEUX
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Eiken Chemical Co., Ltd.
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Hologic, Inc.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Pro Lab Diagnostics Inc.
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. QIAGEN
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. F. Hoffmann-La Roche Ltd.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Takara Bio Inc.
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives
  • 7.4.12. Thermo Fisher Scientific Inc.
    • 7.4.12.1. Company overview
    • 7.4.12.2. Financial performance
    • 7.4.12.3. Product benchmarking
    • 7.4.12.4. Strategic initiatives

관련자료